Literature DB >> 12734408

Variability or conservation of hepatitis C virus hypervariable region 1? Implications for immune responses.

Mario U Mondelli1, Antonella Cerino, Annalisa Meola, Alfredo Nicosia.   

Abstract

The hypervariable region 1 (HVR1) of the E2 protein of hepatitis C virus (HCV) is highly heterogeneous in its primary sequence and is responsible for significant inter- and intra-individual variation of the infecting virus, which may represent an important pathogenetic mechanism leading to immune escape and persistent infection. A binding site for neutralizing antibodies (Ab) has also been allegedly identified in this region. Prospective studies of serological responses to synthetic oligopeptides derived from naturally-occurring HVR1 sequences showed promiscuous recognition of HVR1 variants in most patients via binding to C-terminal amino acid residues with conserved physicochemical properties. Monoclonal antibodies generated by immunization of mice with peptides derived from natural HVR1 sequences were shown to recognize several HVR1 variants in line with evidence gathered from studies using human sera. In addition, selected mAbs were able to bind HVR1 in the context of a complete soluble form of the E2 glycoprotein, indicating recognition of correctly folded sequences, and were shown to specifically capture circulating and recombinant HCV particles, suggesting that HVR1 is expressed on intact virus particles and therefore potentially able to interact with cellular receptor(s). These findings suggest that it is possible to induce a broadly reactive clonal immune response to multiple HCV variants and that this mechanism could be used in principle to induce protective immunity for a large repertoire of HCV variants.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 12734408     DOI: 10.1007/bf02970149

Source DB:  PubMed          Journal:  J Biosci        ISSN: 0250-5991            Impact factor:   1.826


  40 in total

1.  Production and characterization of monoclonal antibodies specific for a conserved epitope within hepatitis C virus hypervariable region 1.

Authors:  C Li; D Candotti; J P Allain
Journal:  J Virol       Date:  2001-12       Impact factor: 5.103

2.  Antibody responses to hepatitis C virus hypervariable region 1: evidence for cross-reactivity and immune-mediated sequence variation.

Authors:  M U Mondelli; A Cerino; A Lisa; S Brambilla; L Segagni; A Cividini; M Bissolati; G Missale; G Bellati; A Meola; B Bruniercole; A Nicosia; G Galfrè; E Silini
Journal:  Hepatology       Date:  1999-08       Impact factor: 17.425

3.  Characterization of hepatitis C virus E2 glycoprotein interaction with a putative cellular receptor, CD81.

Authors:  M Flint; C Maidens; L D Loomis-Price; C Shotton; J Dubuisson; P Monk; A Higginbottom; S Levy; J A McKeating
Journal:  J Virol       Date:  1999-08       Impact factor: 5.103

4.  Prevention of hepatitis C virus infection in chimpanzees by hyperimmune serum against the hypervariable region 1 of the envelope 2 protein.

Authors:  P Farci; A Shimoda; D Wong; T Cabezon; D De Gioannis; A Strazzera; Y Shimizu; M Shapiro; H J Alter; R H Purcell
Journal:  Proc Natl Acad Sci U S A       Date:  1996-12-24       Impact factor: 11.205

5.  Long-term follow-up of chimpanzees inoculated with the first infectious clone for hepatitis C virus.

Authors:  M E Major; K Mihalik; J Fernandez; J Seidman; D Kleiner; A A Kolykhalov; C M Rice; S M Feinstone
Journal:  J Virol       Date:  1999-04       Impact factor: 5.103

6.  Construction and characterization of chimeric hepatitis C virus E2 glycoproteins: analysis of regions critical for glycoprotein aggregation and CD81 binding.

Authors:  Arvind H Patel; Jonny Wood; Francois Penin; Jean Dubuisson; J A McKeating
Journal:  J Gen Virol       Date:  2000-12       Impact factor: 3.891

7.  The dynamics of hepatitis C virus binding to platelets and 2 mononuclear cell lines.

Authors:  S Hamaia; C Li; J P Allain
Journal:  Blood       Date:  2001-10-15       Impact factor: 22.113

8.  The outcome of acute hepatitis C predicted by the evolution of the viral quasispecies.

Authors:  P Farci; A Shimoda; A Coiana; G Diaz; G Peddis; J C Melpolder; A Strazzera; D Y Chien; S J Munoz; A Balestrieri; R H Purcell; H J Alter
Journal:  Science       Date:  2000-04-14       Impact factor: 47.728

9.  T cell recognition of hypervariable region-1 from hepatitis C virus envelope protein with multiple class II MHC molecules in mice and humans: preferential help for induction of antibodies to the hypervariable region.

Authors:  M Shirai; T Arichi; M Chen; T Masaki; M Nishioka; K Ikeda; H Takahashi; N Enomoto; T Saito; M E Major; T Nakazawa; T Akatsuka; S M Feinstone; J A Berzofsky
Journal:  J Immunol       Date:  1999-01-01       Impact factor: 5.422

10.  Antibodies in human sera specific to hypervariable region 1 of hepatitis C virus can block viral attachment.

Authors:  A Zibert; E Schreier; M Roggendorf
Journal:  Virology       Date:  1995-04-20       Impact factor: 3.616

View more
  6 in total

1.  Basic residues in hypervariable region 1 of hepatitis C virus envelope glycoprotein e2 contribute to virus entry.

Authors:  Nathalie Callens; Yann Ciczora; Birke Bartosch; Ngoc Vu-Dac; François-Loïc Cosset; Jean-Michel Pawlotsky; François Penin; Jean Dubuisson
Journal:  J Virol       Date:  2005-12       Impact factor: 5.103

2.  High diversity of hepatitis C viral quasispecies is associated with early virological response in patients undergoing antiviral therapy.

Authors:  Xiaofeng Fan; Qing Mao; Donghui Zhou; Yang Lu; Jianwei Xing; Yanjuan Xu; Stuart C Ray; Adrian M Di Bisceglie
Journal:  Hepatology       Date:  2009-12       Impact factor: 17.425

3.  Comparison of the Mechanisms of Drug Resistance among HIV, Hepatitis B, and Hepatitis C.

Authors:  Severine Margeridon-Thermet; Robert W Shafer
Journal:  Viruses       Date:  2010-12-01       Impact factor: 5.048

Review 4.  GB Virus C/Hepatitis G Virus Envelope Glycoprotein E2: Computational Molecular Features and Immunoinformatics Study.

Authors:  Mohammad Mahdi Ranjbar; Khodayar Ghorban; Seyed Moayed Alavian; Hossein Keyvani; Maryam Dadmanesh; Abbas Roayaei Ardakany; Mohammad Hassan Motedayen; Alireza Sazmand
Journal:  Hepat Mon       Date:  2013-12-30       Impact factor: 0.660

5.  Correlation between pre-treatment quasispecies complexity and treatment outcome in chronic HCV genotype 3a.

Authors:  Isabelle Moreau; John Levis; Orla Crosbie; Elizabeth Kenny-Walsh; Liam J Fanning
Journal:  Virol J       Date:  2008-07-09       Impact factor: 4.099

6.  Hepatitis C virus hypervariable region 1 variants presented on hepatitis B virus capsid-like particles induce cross-neutralizing antibodies.

Authors:  Milena Lange; Melanie Fiedler; Dorothea Bankwitz; William Osburn; Sergei Viazov; Olena Brovko; Abdel-Rahman Zekri; Yury Khudyakov; Michael Nassal; Paul Pumpens; Thomas Pietschmann; Jörg Timm; Michael Roggendorf; Andreas Walker
Journal:  PLoS One       Date:  2014-07-11       Impact factor: 3.240

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.